Heron shares fly up af­ter FDA (fi­nal­ly) ap­proves its drug to rein in chemo side ef­fects

Shares of Red­wood City, CA-based Heron Ther­a­peu­tics $HRTX shot up 20% on Wednes­day morn­ing af­ter the biotech an­nounced that the FDA has at long last ap­proved its sus­tained-re­lease for­mu­la­tion of Sus­tol (granisetron) to pre­vent nau­sea and vom­it­ing for pa­tients on chemo. The ap­proval comes af­ter a 6-year reg­u­la­to­ry odyssey for Heron, which start­ed with the first of two FDA re­jec­tions in 2010.

The in­jectable 5-HT3 re­cep­tor an­tag­o­nist us­es Heron’s poly­mer-based de­liv­ery tech to main­tain ef­fi­ca­cy for five or more days for pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER